This research effort is led by our Translational Research team and focuses on optimizing our technology. This study is not intended to treat Alzheimer’s disease. Participation is compensated.
The RUBY Study aims to inform the development of a therapy for Alzheimer’s disease.
One to Three Visits, Two to Three Hours Each Visit
This survey will determine your eligibility for participation in our study. If you qualify, our team will reach out to provide additional details and next steps.
Compensation is provided if you are enrolled in any of our study visits.
If you fit all of the following criteria, you may be eligible for our study
Men and women living in the Greater Boston area
55+ years old
Adults not experiencing early symptoms of Alzheimer’s disease such as unclear thinking and memory loss
Alzheimer’s disease is a form of dementia characterized by the
progressive increase of memory impairment. This disease is also
associated with the build-up of sticky plaques and tangles of certain proteins in the brain (tau and beta-amyloid).
Research from MIT demonstrated that flickering lights and sounds can induce specific pattern of brain activity (neural oscillations). This research, conducted in mice, showed important effects on multiple aspects of Alzheimer’s (e.g., tau and amyloid reduction, and memory improvement).
The GARNET Study is translating this research for human application in order to develop a possible therapy for Alzheimer’s disease.